1. Home
  2. PMM vs TLSI Comparison

PMM vs TLSI Comparison

Compare PMM & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Putnam Managed Municipal Income Trust

PMM

Putnam Managed Municipal Income Trust

N/A

Current Price

$5.82

Market Cap

269.4M

Sector

Finance

ML Signal

N/A

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

N/A

Current Price

$4.06

Market Cap

250.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PMM
TLSI
Founded
1989
2010
Country
United States
United States
Employees
N/A
102
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
269.4M
250.0M
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
PMM
TLSI
Price
$5.82
$4.06
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $10.40
AVG Volume (30 Days)
229.7K
★ 304.6K
Earning Date
01-01-0001
11-12-2026
Dividend Yield
★ 4.68%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $45,151,000.00
Revenue This Year
N/A
$17.65
Revenue Next Year
N/A
$40.27
P/E Ratio
$27.43
★ N/A
Revenue Growth
N/A
★ 53.41
52 Week Low
$5.39
$2.20
52 Week High
$6.60
$7.95

Technical Indicators

Market Signals
Indicator
PMM
TLSI
Relative Strength Index (RSI) 53.06 33.33
Support Level $5.39 $3.82
Resistance Level $6.35 $4.47
Average True Range (ATR) 0.14 0.37
MACD 0.04 -0.04
Stochastic Oscillator 95.60 5.79

Price Performance

Historical Comparison
PMM
TLSI

About PMM Putnam Managed Municipal Income Trust

Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: